Prescribing Information
Important Safety Information
Patient Site

FDA Approved and Available - CUVRIORTM

(trientine tetrahydrochloride)

CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson Disease who are de-coppered and tolerant to penicillamine. 1
Learn More

Why Choose
CUVRIOR?

CUVRIOR is the first advance in Wilson Disease in over 30 years, bringing the advantages of an innovative formulation of trientine tetrahydrochloride (4HCl) specifically designed for patients with Wilson Disease. 1
CUVRIOR demonstrated efficacy noninferior to D-penicillamine (DPA) in the first prospective head-to-head trial of any trientine chelating agent. 2
Find out more
CUVRIOR provides a predictable and fully characterized pharmacokinetic profile, with a fast absorption and improved bioavailability compared to a dihydrochloride formulation of trientine. 3
Find out more
CUVRIOR is well-tolerated, with a similar safety profile to other formulations of trientine. 3
Find out more
CUVRIOR provides convenient dosing, with a small tablet size, stability at room temperature, and being supplied in an easy-to-use child-proof blister pack. 1
Find out more

References:

  1. CUVRIORTM (trientine tetrahydrochloride) Prescribing Information.
  2. Schilsky M L, et al. Lancet Gastroenterol Hepatol. 2022;7(12):1092-1102.
  3. Weiss K H, et al. Eur J Drug Metab Pharmacokinet. 2021;46(5):665-675.

Indication & Important Safety Information

CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson Disease who are de-coppered and tolerant to penicillamine. Please see full Prescribing Information.
Important Safety Information
INDICATION
CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson Disease who are de-coppered and tolerant to penicillamine.
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • CUVRIOR is contraindicated in patients with hypersensitivity to trientine or to any of the excipients in CUVRIOR.

WARNINGS AND PRECAUTIONS

  • Potential for Worsening of Clinical Symptoms at Initiation of Therapy, including neurological deterioration, may occur at the beginning of CUVRIOR therapy due to mobilization of excess stores of copper. Adjust the dosage or discontinue therapy if clinical condition worsens. Evaluate serum non-ceruloplasmin copper (NCC) levels or 24-hour urinary copper excretion (UCE) when initiating treatment, after 3 months, and approximately every 6 months thereafter.
  • Copper Deficiency may develop following treatment with CUVRIOR. Periodic monitoring is required.
  • Iron Deficiency may develop following treatment with CUVRIOR. If iron deficiency develops, a short course of iron supplementation may be given.
  • Hypersensitivity Reactions, characterized by rash, have been reported with the use of trientine. Rash was reported in 12% (3/26) of CUVRIOR-treated patients, and one patient discontinued treatment due to rash. If rash or other hypersensitivity reaction occurs, consider discontinuing CUVRIOR.

ADVERSE REACTIONS

The most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings.

DRUG INTERACTIONS

  • Mineral Supplements (e.g. iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable, take CUVRIOR at least 2 hours before or 2 hours after iron and take CUVRIOR at least 1 hour before or 2 hours after other mineral supplements.
  • Other Drugs for Oral Administration: Take CUVRIOR at least 1 hour apart from any other oral drug

Please see full Prescribing Information

To report SUSPECTED ADVERSE REACTIONS, call Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch